Vitamin D deficiency has been associated with increased incidence of diabetes, both in humans and in animal models. In addition, an association between vitamin D receptor (VDR) gene polymorphisms and diabetes has also been described. However, the involvement of VDR in the development of diabetes, specifically in pancreatic β-cells, has not been elucidated yet. Here, we aimed to study the role of VDR in β-cells in the pathophysiology of diabetes. Our results indicate that Vdr expression was modulated by glucose in healthy islets and decreased in islets from both type 1 diabetes and type 2 diabetes mouse models. In addition, transgenic mice overexpressing VDR in β-cells were protected against streptozotocin-induced diabetes and presented a preserved β-cell mass and a reduction in islet inflammation. Altogether, these results suggest that sustained VDR levels in β-cells may preserve β-cell mass and β-cell function and protect against diabetes.
Vitamin D deficiency has been associated with diabetes, both in individuals with type 1 diabetes (T1D) and insulin resistance/type 2 diabetes (T2D) (1–3). In addition, a parallel increase in the prevalence of diabetes and in vitamin D deficiency incidence worldwide has been observed, which may result from both deficient sun exposure, involved in vitamin D synthesis by the skin, and inadequate dietary supply (4). Vitamin D exerts its actions mainly through its binding to vitamin D receptor (VDR), and VDR gene polymorphisms have also been associated with the risk of T2D in different ethnic populations (5). Likewise, two single nucleotide polymorphisms in the VDR gene have been associated with T1D (6). This strongly suggests an essential role of the vitamin D/VDR axis in diabetes, although the mechanisms have not yet been elucidated.
VDR belongs to the steroid hormone receptor superfamily, and it is widely expressed in several cell types where it is known to regulate key cellular processes such as proliferation, differentiation, apoptosis, and immunomodulation (7). In addition, genome-wide VDR-binding chromatin immunoprecipitation sequencing (ChIP-seq) data revealed that an important part of target genes is involved in metabolism (8–10). Moreover, VDR is expressed in a wide variety of immune cells, and vitamin D is a known immunomodulator in both the innate and adaptive arms of the immune system (11). In particular, vitamin D can promote immune tolerance and has immunosuppressive properties (11,12). Vitamin D exposure also causes T cells to change their cytokine production from a proinflammatory to an anti-inflammatory profile (13). It has been hypothesized that vitamin D may have a protective role in diabetes since the immune system is involved in the development of both T1D and T2D (14,15).
VDR is also expressed in several insulin-responsive metabolic tissues, such as the liver, skeletal muscle, or adipose tissue, and it has been reported that vitamin D may improve insulin sensitivity of these tissues (16). Vitamin D may directly increase insulin receptor expression, and thereby enhance insulin stimulation of glucose transport, or indirectly decrease insulin resistance by decreasing inflammatory responses, one of the causes of insulin resistance (16).
Pancreatic islets also express VDR and can metabolize inactive 25-hydroxyvitamin D3 to active 1,25 (OH)2D3 (17). Vitamin D has been reported to exert beneficial effects on glucose tolerance enhancing β-cell function (18,19). Studies in cultured rat islets demonstrated that synthesis and release of insulin may be enhanced by treatment with high doses of vitamin D (20). Moreover, mice with VDR deficiency presented impaired glucose tolerance, defective insulin secretion, and a reduction in insulin mRNA content, suggesting that VDR is a key factor in β-cell function (21). However, the role of VDR, specifically in β-cells, during the development of diabetes remains unknown.
Thus, here we aimed to study the role of VDR in the β-cell in the pathophysiology of diabetes. We found that Vdr expression is decreased in islets from both T1D and T2D mouse models. We also demonstrated that overexpression of VDR in β-cells of transgenic (Tg) mice counteracted experimental diabetes, providing evidence that sustained VDR levels in β-cells may preserve β-cell mass and function and protect against diabetes.
Research Design and Methods
Female NOD/LtJ and male BKS.Cg-+Leprdb/+Leprdb OlaHsd (db/db), BKS.Cg-m+/+Leprdb/OlaHsd (db/+), and C57Bl6/SJL mice were used. Heterozygous male Tg mice expressing mouse Igf2 under the control of the rat insulin promoter-I (RIP-I) were used (22). Diabetes was induced by streptozotocin (STZ) as previously described (23). All mice were fed ad libitum with a standard chow diet (2018S Teklad Global; Harlan) and maintained under conditions of controlled temperature and light (12-h light/dark cycles). Where stated, mice were fasted for 16 h. Animal care and experimental procedures were approved by the Ethics Committee in Animal and Human Experimentation of the Universitat Autònoma de Barcelona, Bellaterra, Spain.
Generation of Tg Mice
The RIP-I/Vdr chimeric gene was obtained by introduction of a 3.3-kb EcoRV-EclXI fragment containing the entire mouse Vdr cDNA (Open Biosystems INC, Huntsville, AL) (ref. 3710866, GeneBankBC006716) at the EcoRI site in RIP-I/β-globin expression vector (22). This chimeric gene was microinjected into fertilized mouse eggs from a C57BL6/SJL background. The general procedures used for microinjection and detection were as described (24).
Immunohistochemistry and Histopathology
For immunohistochemical detection of VDR, insulin, glucagon, somatostatin, pancreatic polypeptide, TUNEL, and Ki67, pancreas were fixed for 12–24 h in formalin, embedded in paraffin, and sectioned. Sections were then incubated overnight at 4°C with the following antibodies: rat anti-mouse VDR (clone 9A7; Merck KGaA, Darmstadt, Germany), guinea pig anti-porcine insulin (Sigma Chemical, St Louis, MO), rabbit anti-human glucagon (Signet Laboratories, Dedham, MA), rabbit anti-somatostatin (Serotec, Oxford, U.K.), rabbit anti-human pancreatic polypeptide (ICN Biomedicals), and anti-Ki67 (BD Pharmingen). As secondary antibodies, peroxidase-conjugated rabbit anti-guinea pig IgG (Dako, Glostrup, Denmark), biotinylated goat anti-rabbit (Pierce, Rockford, IL), tetramethylrhodamine isothiocyanate (TRITC)-conjugated goat anti-guinea pig (Molecular probes, Leiden, the Netherlands), biotinyilated goat anti-rabbit (Molecular Probes), biotinylated rabbit anti-rat (Dako), and biotinylated horse anti-mouse (Vector Laboratories, Burlingame, CA) antibodies were used. Streptavidin-conjugated Alexa 488 (Molecular Probes) or streptavidin-conjugated Alexa 568 (Molecular Probes) were used as fluorochromes. Images were obtained with a Nikon Eclipse 90i microscope (Nikon, Tokyo, Japan).
β-Cell and α-cell mass, β-cell replication, and apoptosis determination were performed as previously described (23,25).
Islet Isolation and Culture
Pancreatic islets were isolated as previously described (23) and cultured overnight to recuperate from isolation stress in RPMI-1640 (2.5 mmol/L glucose), supplemented with 1% BSA, 2 mmol/L glutamine, and penicilin/streptomycin at 37°C in an atmosphere of 95% humidified air/5% CO2. To study the effects of glucose on Vdr expression on β-cells, after overnight culture, pools of islets were treated with 2.5 or 9 mmol/L of glucose and 9 mmol/L 2-deoxy-d-glucose. Some of the pools were also cultured with recombinant INS (2 ng/mL) (Sigma). After 8 h of treatment, islets were hand-picked and processed to obtain RNA.
Gene Expression Analysis
For quantitative PCR analysis, total RNA was extracted from isolated islets using Tripure Isolation Reagent (Roche Molecular Biochemicals) and Rneasy Micro Kit (Qiagen, Hilden, Germany). Total RNA (1 µg) was reverse-transcribed for 1 h at 37°C with Transcriptor First Strand cDNA Synthesis Kit (Roche). Quantitative PCR was performed in a Light Cycler 480 II (Roche) using Light Cycler 480 SYBR Green I Master mix (Roche). Values were normalized to Rplp0 as housekeeping. The primers listed in Table 1 (Supplementary Data) were used for murine islets.
Hormone and Metabolite Assays
Blood glucose levels and serum insulin concentrations were measured as previously described (23). A glucose tolerance test was performed as previously described (23). For insulin release determination, glucose (3 g/kg body weight) was injected intraperitoneally, and venous blood from the tail vein was collected at 0, 2, 5, 15, and 30 min in prechilled tubes (Microvette CB 300; SARSTEDT), which was immediately centrifuged to separate plasma and was stored at −20°C. Insulin levels from an insulin release test were measured by ELISA (Crystal Chemical, Chicago, IL).
All values are expressed as the mean ± SEM. Differences between two means were compared by Student t test, and differences between three or more means were analyzed by one-way ANOVA or two-way ANOVA tests using GraphPad Prism software (version 7.00; GraphPad Software). A P value <0.05 was considered statistically significant. Correlations were determined by nonparametric Spearman correlation test using the computer program GraphPad Prism (version 7.00; GraphPad Software).
Data and Resource Availability
To characterize the expression in human β-cells of different genes, such as VDR, INS, or SLC2A2, we used publicly available data sets from Gene Expression Omnibus (GEO) (26) and ArrayExpress databases (27): GSE20966 (28) and E-CBIL-20 (29). For each data set, the publicly available normalized expression levels for each gene were used. When different probes were detecting the expression of the same gene, their genomic locations were determined to assess its relevance. Data were then plotted as relative signal expression.
VDR Expression Is Reduced in Islets From Diabetic Mice
To study the regulation of Vdr gene expression in islets during the diabetic process, Vdr mRNA levels were measured in islets of several diabetic animal models. In islets from nonobese diabetic (NOD) mice (Fig. 1A), the most common type 1 diabetic mouse model, which shows infiltrated islets and β-cell reduction related to glycemia (Supplementary Fig. 1A), Vdr mRNA levels were decreased in hyperglycemic mice compared with normoglycemic littermates (Fig. 1B). This reduction was observed in parallel with a decline in the expression levels of β-cell marker genes, such as insulin (Ins), solute carrier family member 2 (Slc2a2 or Glut2), and glucokinase (Gck) (Fig. 1B). In addition, islet glucagon (Gcg) and uncoupling protein 2 (Ucp2) expression remained unchanged (Fig. 1B). Similarly, in islets from STZ-induced diabetic mice (Fig. 1C), expression of Vdr and β-cell gene markers was also reduced (Fig. 1D). In contrast, Gcg expression was unaltered, and Ucp2 expression presented a clear trend to increase in STZ islets (Fig. 1D). Moreover, Vdr expression was measured in islets from a Tg T2D mouse model in which islets were hyperplasic because of IGF2 overexpression specifically in β-cells (22,25). These Tg mice (Tg-IGF2) develop a prediabetic state with disrupted islet structure, β-cell dysfunction, altered glucose homeostasis, and islet hyperplasia (25) (Supplementary Fig. 1B). Similar to those in the T1D models, islets from prediabetic Tg-IGF2 mice also showed a clear decrease in Vdr expression together with a reduction in β-cell gene markers (Fig. 1E and F). Likewise, a reduction in Vdr expression levels and a decrease in β-cell gene markers were also observed in the well-established T2D model db/db mice, which also displayed unchanged islet Gcg expression and a significant increase of Ucp2 mRNA levels (Fig. 1G and H). Moreover, the correlation between Vdr expression levels and glycemia was examined in T1D and T2D models. Clearly, Vdr expression levels in islets correlated with glucose levels in all analyzed T1D and T2D mice models (Supplementary Fig. 1C–F). It is noteworthy that analysis of human islets from healthy and T2D patients from two public available gene expression data set GSE20966 (28) (Fig. 2A) and E-CBIL-20 (29) (Fig. 2B) revealed a nonsignificant trend toward a reduction in the expression levels of VDR and SLC2A2 in islets from T2D patients. These results from different diabetic mouse models and human samples provided evidence that Vdr expression in islets was reduced in conditions of hyperglycemia.
VDR Expression Is Controlled by Glucose
To further explore the regulation of Vdr expression by changes in glucose levels, Vdr expression was measured in islets from fed and fasted wild-type (Wt) mice (Fig. 3A). Unexpectedly, our results showed a marked reduction in Vdr mRNA levels in islets from fasted mice compared with islets from fed mice (Fig. 3B). The decrease in Vdr expression in fasted conditions was also parallel to a significant reduction in Ins and Slc2a2 gene expression (Fig. 3B). We next evaluated the effects of changes in glucose concentration on Vdr gene expression in cultured islets. In islets incubated with high glucose, Vdr mRNA levels were increased, whereas this increase was blunted in islets treated with nonmetabolizable 2-deoxy-d-glucose (Fig. 3C), suggesting that glucose metabolization is required to induce Vdr expression. In addition, to examine the effects of insulin on Vdr expression, islets were treated with both insulin and 2-deoxy-d-glucose. Insulin in the presence of nonmetabolizable glucose did not modify either Vdr or Ins mRNA levels (Fig. 3C and D).
Altogether, these results indicate that Vdr gene expression in islets is controlled by glucose, which supports the idea that VDR may play a role in β-cell function.
β-Cell VDR Overexpression Ameliorates Diabetes in Mice
To unravel the role of VDR in β-cells, Tg mice overexpressing VDR, specifically in β-cells, were generated. Three lines of Tg mice (Tg1, Tg3, and Tg4) were obtained that overexpressed murine Vdr under the control of RIP-I. Islets from Tg mice presented higher levels of Vdr mRNAs than Wt littermates (Fig. 4A and Supplementary Fig. 2A). Immunohistochemical analysis revealed that VDR overexpression was detected, specifically in insulin-positive cells (Fig. 4B and Supplementary Fig. 2B). In addition, glycemia and insulinemia remained unchanged in Tg mice when compared with Wt mice (Fig. 4C and D and Supplementary Fig. 2C and D). Since similar results were obtained in the three lines for a number of analyses and to avoid an unnecessary increase in the number of mice studied, Tg3 was selected for a further phenotyping. In accordance with normal glucose and insulin levels, both 4- and 8-month-old Tg mice exhibited normal glucose tolerance (Fig. 4E and Supplementary Fig. 3A). In addition, glucose-stimulated insulin release in 4-month-old mice was not significantly altered (Supplementary Fig. 3B), indicating that VDR overexpression did not modify β-cell function. To evaluate if VDR overexpression affected islet cell mass and distribution, β- and α-cell morphometric analyses were performed. Both 4- and 10-month-old Tg3 mice presented nonsignificant changes in β-cell mass compared with Wt littermates (Fig. 4F and Supplementary Fig. 3C). Immunohistochemical analysis against insulin revealed no differences in islet number (0.12 ± 0.01 and 0.08 ± 0.02 islet number/mg pancreas in Wt and Tg3, respectively) and β-cell distribution in the pancreas between Wt and Tg3 mice (Fig. 4G). Similarly, no alterations in α-cell mass and distribution were observed in 4- and 10-month-old mice (Fig. 4G and Supplementary Fig. 3D and E).
Next, to examine the effects of VDR overexpression during the diabetic process, Wt and Tg3 mice received five daily consecutive injections of a standard dose of STZ (50 mg/kg) to induce diabetes. After STZ treatment, Wt mice displayed severe hyperglycemia, and 100% of mice developed overt diabetes. However, only 60% of treated Tg mice were diabetic and presented a less severe hyperglycemia at the end of the study (Fig. 5A and Supplementary Fig. 4A and B). In Tg3 mice, glycemia improvement was even more evident in fasting conditions (Fig. 5B). Similar results were obtained when STZ treatment was administered to Tg1 mice (Supplementary Fig. 4C and D). As previously shown, Vdr expression declined in islets from Wt mice after STZ treatment (Fig. 5C). In contrast, although Tg3 mice presented a similar Vdr reduction after STZ treatment, they sustained high Vdr expression levels (Fig. 5C).
Immunohistochemical analysis against insulin also clearly revealed that after STZ treatment, Tg mice presented a higher number and area of insulin-positive islets in the pancreas compared with Wt mice, which showed few insulin-positive β-cells (Fig. 5E and F). These results correlated with higher insulin levels in Tg3 compared with Wt mice (Fig. 5D). The observed β-cell mass maintenance was parallel to a lower decrease in mRNA levels of β-cell gene markers such as Ins1, Slc2a2, and GcK after STZ treatment in Tg3 islets (Supplementary Fig. 4E).
The maintenance of pancreatic β-cell mass basically depends on two mechanisms: apoptosis and replication (30). Both mechanisms were explored in mice treated with STZ by morphometric analysis. TUNEL-positive β-cell percentage, an index of apoptosis, was similar in Wt and Tg3 mice, indicating that VDR overexpression did not protect β-cell from apoptosis (Fig. 6A). In contrast, Tg3 islets showed a clear increase in proliferation cell markers Pcna and CdK2 (Fig. 6B and C). In addition, a higher Ki67-positive β-cell percentage, which is a classical β-cell replication index, was detected in Tg3 islets compared with Wt (Fig. 6D and E). Thus, these results indicated that maintenance of the proliferation capacity may be involved in β-cell preservation in Tg3 mice after STZ damage.
The presence of inflammation was examined in islets by measuring islet proinflammatory and anti-inflammatory markers. Tg3 mice showed higher levels of anti-inflammatory A20 mRNA and a reduction of proinflammatory Tnfa, Tgfb, and H2-Aa mRNA levels related to Wt mice (Fig. 6F). In addition, Ucp2, which has been reported to be an inhibitor of A20 gene expression, was downregulated in Tg3 compared with Wt islets before and after STZ treatment (Supplementary Fig. 4F). Altogether, these data suggested that sustained VDR expression levels protected Tg mice to develop severe hyperglycemia, partially preserving β-cell mass and reducing local inflammation and diabetic consequences.
Since standard doses of STZ may have very toxic consequences (31), the effects of VDR overexpression were also explored in diabetic mice induced by very low doses of STZ (30 mg/kg) (five doses consecutive days) (+STZlow). After STZlow treatment, Wt mice developed hyperglycemia, and about 50% of them became overtly diabetic (Fig. 7A and B). In contrast, Tg3+STZlow mice maintained normoglycemia during all the study with no signs of diabetes (Fig. 7A and B). This improvement was also observed in fasted glycemia, which was clearly lower in Tg3+STZlow mice (Fig. 7C), and in insulin levels that were higher in Tg3+STZlow mice compared with Wt+STZlow mice (Fig. 7D) and were similar to Wt healthy mice (Fig. 4D). In addition, 2 months after STZlow treatment, Tg3+STZlow mice showed an improvement in glucose tolerance compared with Wt+STZlow mice (Fig. 7E). Gene expression analysis of islets at the end of the study revealed a decrease in Vdr expression in Wt+STZlow as observed previously (Figs. 5C and 8A), whereas Tg3+STZlow mice maintained high levels of Vdr, correlating with sustained levels of Ins expression (Fig. 8A). β-cell mass was also higher in Tg3+STZlow mice, accordingly to glucose and insulin values. Likewise, immunohistochemical analysis of the pancreas revealed few insulin-positive islets in Wt+STZlow mice, while Tg3+STZlow mice presented a normal number of insulin-positive islets according to β-cell mass data (Fig. 8B and C).
Overall, these results provide evidence that sustained levels of VDR during the diabetic process revert hyperglycemia onset, improve glucose tolerance, and maintain β-cell mass.
The role of vitamin D in the protection against diabetes is now widely accepted, although the underlying mechanisms are mainly unknown. In agreement with a protective role of vitamin D, vitamin D deficiency has been associated with diabetes (1). Similarly, polymorphisms in the Vdr gene, which lead to a significant decrease of mRNA and VDR protein levels, are a risk factor for diabetes development (32). Here, we clearly demonstrate that Vdr expression in mice is downregulated in islets during the development of both T1D and T2D. It is noteworthy that our results obtained from publicly available data sets also showed a trend toward a reduction in VDR expression in human islets from T2D patients. These results were consistent with previous reports showing a reduction in Vdr expression in pancreas from STZ-treated mice and rats (17). In this work, we provided evidence that Vdr reduction also occurs in islets from NOD mice that spontaneously develop diabetes and share many features with human T1D (33). In addition, we observed decreased Vdr levels in two different mouse models of T2D with β-cell hyperplasia (25,34).
Altogether, our results suggested that Vdr downregulation in β-cells may be a common feature of diabetes and that this reduction, along with a reduction in the expression of other β-cell markers, may be the result of β-cell loss/dedifferentation in diabetic islets, one of the common features of both T1D and T2D. VDR decrease was also associated with hyperglycemia, the major hallmark of diabetes. Indeed, Vdr expression was negatively correlated to circulating glucose levels in all the diabetic models studied here. Unexpectedly, we also showed that Vdr expression was decreased when circulating glucose levels were physiologically low, i.e., during fasting. Our results obtained from an in vitro study in cultured islets further indicated that Vdr expression was stimulated by glucose. Thus, although we cannot discard that decreased Vdr expression was due to β-cell loss during diabetes, our results may also be explained by the fact that diabetes is associated with low intracellular glucose levels resulting from decreased glucose uptake and a decrease in glucose sensing players, such as GLUT2 in β-cells (35).
Likewise, in fasted conditions, β-cells present similar low intracellular glucose. Thus, we can hypothesize that despite hyperglycemia, the low intracellular glucose levels may be responsible for Vdr downregulation. Accordingly, in islets from all of the diabetic mouse models analyzed, a reduction in expression of genes involved in glucose uptake in β-cells, the glucose transporter Slc2a2 and the glucose-phosphorylating enzyme Gck, was parallel to Vdr downregulation. In human islets from T2D patients, a parallel nonsignificant trend to decrease of SLC2A2 and VDR expression has also been observed. Thus, in humans, decreased glucose uptake in β-cells may also lead to a reduction in VDR expression. However, the mechanisms of regulation of β-cell VDR expression in humans remain to be elucidated. In addition, although our results suggest for the first time, that glucose metabolism may modulate positively Vdr expression, further studies are necessary to carefully explore this issue. It is also noteworthy that Vdr expression in islets declined in fasted compared with fed state, corroborating the importance of glucose metabolism for physiological regulation of Vdr expression. Accordingly, it has been reported recently that fasting-induced transcription factors repress vitamin D bioactivation (36). Thus, our findings reveal that both physiological acute changes in glucose concentration and pathophysiological disruption of glucose uptake alter Vdr gene expression in islets and may be responsible for Vdr decreased expression during diabetes.
Our results also support that VDR deficiency may have an impact on β-cell function alterations during diabetes. Results obtained from mice lacking functional Vdr indicate that VDR loss leads to a reduction in insulin mRNA levels and a deficit in insulin secretion (21). In accordance with this, we observed a decrease in insulin gene expression levels parallel to Vdr reduction in islets from diabetic mice. Moreover, treatment with vitamin D increased Ins1 mRNA expression in control animals, but this effect was lost in STZ-treated mice, possibly because of a decrease in Vdr expression in islets (17). These results suggest that VDR may be involved in Ins1 transcription in mouse pancreas (17). However, so far, no vitamin D response elements have been identified in the human or mouse insulin gene promoters. VDR-deficient mice are glucose intolerant, probably due in part to defects of the β-cell function, but the absence of VDR in other tissues may also contribute to their phenotype (21).
In this study, we found that Tg mice overexpressing VDR specifically in β-cells were resistant to the development of STZ-induced diabetes. Our results show a clear protective effect of sustained VDR levels in β-cell in front of STZ damage. It has been described that multiple doses of STZ induce diabetes through an increase in inflammatory cytokines, β-cell functional defects, and finally β-cell loss (37). Tg mice overexpressing VDR presented a preservation of β-cell mass, at least in part by maintaining β-cell replication capacity in front of STZ damage. In agreement with these results, it has recently been reported that VDR activation leads to an induction of β-cell replication (38). In addition, VDR overexpression partially protected Tg mice from islet inflammation, reducing the expression of inflammatory markers in islets. This reduction in inflammation and the subsequent protection against diabetes may have been mediated by VDR, as suggested by the fact that vitamin D, or its nonhypercalcemic analog, significantly inhibits insulitis and prevents or delays the onset of diabetes in NOD mice (13,39,40). In addition, the activation of VDR in human β-like cells is able to counteract the inflammatory response induced by cytokines and maintain β-cell functionality (38). In contrast, knockdown of VDR led to an increased cytokine-induced cell death in human β-like cells and to a reduction in the expression of key β-cell genes in cytokine-treated rat β-cells INS1 (38). All of these data suggest that VDR may reduce the inflammatory milieu in islets and therefore maintain β-cell mass and function resulting in a protection against diabetes development. Therefore, we demonstrated that sustained VDR levels in β-cells may protect against diabetes-induced damages by increasing β-cell functional target genes, decreasing inflammation and maintaining β-cell proliferation capacity.
Data from animal studies show that although vitamin D administration may delay the onset of diabetes in NOD mice, no or limited benefit has been observed by the administration of a vitamin D analog on β-cell damage after STZ treatment in mice (38). Interestingly, pharmacologically induced VDR signaling by a synthetic ligand in combination with a VDR-downstream modulator is able to partially restore β-cell function and glucose homeostasis in various T2D and T1D mouse models. Nevertheless, these effects were lost when the VDR synthetic ligand was used alone (38). In light of our results, this lack of effectiveness of vitamin D analogs or VDR ligands may be due to reduced Vdr expression levels in diabetic mice.
In humans, clinical data of effectiveness of vitamin D supplements are controversial. Although some data reveal beneficious effects of vitamin D supplementation on glucose metabolism (41,42), others report no effect of vitamin D supplements (43,44). The results of supplementation may be influenced by factors such as baseline vitamin D status, variability in dosages and forms of vitamin D used, duration of the intervention, or heterogeneity of the patients (45). It has also been suggested that genetic variation in VDR may influence metabolic effects of vitamin D supplementation in T2D (46). Our data clearly point out that variations in VDR expression in diabetic patients may also influence the outcomes of vitamin D supplementation. Therefore, a better knowledge of the VDR regulation in diabetes is necessary to define appropriate strategies of supplementation to improve glycemic control and metabolic alterations.
Although various studies described genetic variations in the VDR gene as a risk factor for T1D and T2D development, contradictory results about the association between VDR single nucleotide polymorphisms and T2D have been reported (47–49). While genetic variations may not be responsible for diabetes development, a pathophysiological decrease in VDR expression may lead to a loss of protection against β-cell damage. As evidenced here, VDR expression maintenance might be essential to counteract β-cell damage in the diabetic process and to protect against diabetes development. Thus, future strategies for treatment of diabetes should be based on a better knowledge of mechanisms underlying VDR downregulation during diabetes and address restoration of VDR levels.
Acknowledgments. The authors thank Malcolm Watford (Rutgers University, New Brunswick, New Jersey) and Ivet Elias (Universitat Autònoma de Barcelona, Bellaterra, Spain), for helpful discussion and Aina Bonet, Marc Leal, Albert Ribera, Marta Moya, Jennifer Barrero, and Lidia Hernández (Universitat Autònoma de Barcelona, Bellaterra, Spain) for technical support.
Funding. This work was supported by grants from FEDER/Ministerio de Ciencia, Innovación y Universidades – Agencia Estatal de Investigación (SAF2017-86166-R), Generalitat de Catalunya (ICREA Academia Award to F.B.), Spain. G.E. received a predoctoral fellowship from Generalitat de Catalunya, Spain.
Duality of Interest. No potential conflicts of interest relevant to this article were reported.
Author Contributions. M.Mor. and L.V. designed experiments, generated reagents, performed experiments, and wrote and edited the manuscript. S.F. designed experiments and wrote and edited the manuscript. C.M. generated reagents, performed experiments, and contributed to discussions. G.E., T.F., M.Mol., and E.C. generated reagents and performed experiments. J.R. analyzed human data and contributed to discussion. A.P. generated transgenic mice and contributed to discussion. N.T. designed experiments and contributed to discussions. F.B. and A.C. designed experiments and wrote and edited the manuscript. A.C. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
- Received August 2, 2019.
- Accepted February 14, 2020.
- © 2020 by the American Diabetes Association